2013 Deals Review Finds Spec Pharma, Bolt-Ons Dominated M&A
Executive Summary
According to the Strategic Transactions database, 2013 saw 92 deals involving biopharma M&A completed or close to completion; the most active participants were specialty pharma companies, with only a handful of big pharmas committing to buying up assets.